Why Implantable Device CERs Fail First Review—Real Audit Patterns
I reviewed twelve implantable device submissions last year that failed at first Notified Body assessment. Different devices. Different manufacturers. But the same three deficiencies appeared in almost every rejection letter.
In This Article
The patterns are consistent. When a clinical evaluation report for an implantable device returns with major deficiencies, it’s rarely because of missing documents. It’s because the clinical rationale collapses under scrutiny.
What looks sufficient on your side does not survive the first technical review. The equivalence claim you spent months building gets dismantled in two paragraphs. The literature search that passed internal review gets flagged for systematic bias.
This is the fifth post in our series on implantable devices. We’re looking at what actually fails and why reviewers reject it.
The Weight of Evidence for Permanent Implants
Implantable devices carry a different burden. Once placed inside the body, they cannot be easily removed or adjusted. The clinical consequences of failure are immediate and often irreversible.
MDCG 2020-13 makes this explicit. For implantable Class III devices, equivalence claims face heightened scrutiny. The clinical data requirements expand. The margin for assumptions shrinks.
But manufacturers still approach these CERs with the same template structure used for lower-risk devices. The framework stays the same. The depth does not match the risk profile.
The regulatory expectation for implantable devices is not just more data. It’s a different quality of reasoning. Reviewers expect you to anticipate failure modes that take years to manifest and justify safety based on mechanisms, not just outcomes.
Pattern One: Equivalence Claims Built on Surface Features
The first deficiency pattern appears in the equivalence section. Manufacturers claim equivalence based on material composition, design intent, or indications for use. But they miss the clinical characteristics that matter under MDR.
I see tables comparing titanium alloy grades, coating thickness, or fixation methods. What I don’t see is clinical performance under load, tissue response over time, or failure modes in real anatomical conditions.
Equivalence under MDR Annex XIV requires clinical equivalence, not just technical similarity. That means demonstrating that the devices produce the same clinical outcomes in the same clinical conditions for the same duration.
For an implantable device, this includes long-term biological response, mechanical stability, and the absence of late-onset complications. If your equivalent device has five-year follow-up data and yours has two years, the gap is not bridged by material certificates.
Equivalence tables list design features and materials but fail to demonstrate that both devices perform identically in vivo over the intended lifetime. Reviewers reject this because it does not address the clinical risk of long-term implantation.
What Reviewers Actually Check
When I review an equivalence claim for an implantable device, I start with the failure modes. I look for fracture rates, migration data, infection rates, and revision surgery triggers.
If the claimed equivalent device has published data on ten-year survival and yours does not, the equivalence claim requires justification for that gap. You must explain why shorter follow-up is sufficient or commit to generating the missing data through PMCF.
Most submissions skip this step. They assume similarity in design implies similarity in clinical outcome. It does not.
Pattern Two: Literature Reviews That Miss Long-Term Complications
The second pattern shows up in the clinical data section. The literature review includes studies on the device, but the follow-up duration is too short.
Implantable devices cause complications that emerge years after surgery. Osteolysis around joint implants. Late stent thrombosis. Capsular contracture. Chronic inflammatory response.
If your literature review stops at twelve months and your device is intended to remain implanted for life, you have not covered the clinical risk profile. Reviewers know this. They flag it immediately.
MDCG 2020-6 requires that the clinical data cover the full lifecycle of the device. For implantables, that means following patients until the device is removed or replaced, or until long-term stability is demonstrated.
But I still see CERs that cite only short-term pivotal trials and ignore the post-market registries that show what happens at five or ten years.
Literature reviews include only studies with follow-up under two years, while the device is intended for permanent implantation. This creates an evidence gap that cannot be closed without new data generation or robust PMCF commitments.
Why Short-Term Data Is Not Sufficient
Short-term studies show whether the device works initially. They do not show whether it continues to work safely over time.
For an implantable device, the question is not just
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). MDCG 2020-6, MDCG 2020-13
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
